![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Context: Circulating tumor DNA (ctDNA) is a promising biomarker in cancer.
Materials and methods: We generated xenograft models of cancer and detected ctDNA in plasma by qRCR targeting human AluJ sequences.
Results: Our assay reached single cell sensitivity in vitro and a correlation between ctDNA amount and tumor size was observed in vivo. Treatment with a mitogen activated protein kinase kinase (MEK)-inhibitor (BAY 869766) reduced ctDNA levels. Using this assay, we also confirmed that high levels of cell-free DNA are found in cancer patients compared to healthy individuals.
Discussion and conclusion: We show that ctDNA may be useful biomarker for monitoring tumor growth and treatment response.
Keywords::
Acknowledgments
We are grateful to Tanja Rose, Daniela Foerster, Marcus Conrad, and Claudia Schneider for excellent support with the xenografts models.
Declaration of interest
All authors, except Johanna Schiller and Daniel Schuetzmann are full-time employees of Bayer Pharma AG.